Roche diabetes app replaces blood glucose meter
Diabetes patients can use an app developed by Roche to determine their blood sugar levels on the basis of two photos taken on a cell phone camera. The Basel-based pharma group has now received the CE Mark for its app, paving the way for it to be marketed throughout Europe and in other countries around the world.
Roche in Basel (img: Roche)
Roche has removed the need for diabetes patients to use blood sugar measuring devices. The Accu-Chek Sugar View app developed by the Basel-based pharmaceutical company allows blood sugar levels to be tested using special test strips and two photos taken with a cell phone camera, as outlined in a press release. Roche has now received the CE Mark for its app, which confirms that the product complies with the applicable requirements. The CE Mark is a prerequisite for successful marketing across Europe and in other countries.
Roche will now make the app widely available for certain smartphone models via the Google Play Store. “The broad launch of this state-of-the art digital solution can offer a huge benefit to people in-between doctors’ visits and to those not having access to appropriate diabetes care and blood glucose monitoring”, explained Marcel Gmünder, Global Head of Roche Diabetes Care, in the press release. An additional advantage is that the app represents an affordable solution for those suffering from diabetes, Gmünder commented further.
Users take an Accu-Chek Active test strip and then take two photos on their smartphone camera. The app leads the user through an easy-to-follow process until a dedicated algorithm assigns the blood glucose result on the test strip to one of the categories ranging from “low” to “very high”. Based on this assessment, the user receives suggested actions including, for example, a prompt to eat something.
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More